MOUNTAIN VIEW, Calif., Sept. 26, 2013 /PRNewswire/ -- IRIDEX (Nasdaq: IRIX) today announced a number of key international conferences and workshops that will feature its proprietary MicroPulse Laser Therapy for the treatment of diabetes and glaucoma related disorders.
The upcoming European Society of Retina Specialists (EURETINA) conference in Hamburg, Germany will feature an official Instructional Course on the use of IRIDEX' MicroPulse Therapy for retinal disorders such as those caused by complications of diabetes. EURETINA is Europe's largest society of retina specialists.
MicroPulse is a vision-preserving laser treatment that does not produce the retinal tissue damage that is often associated with traditional laser therapies.
"Independent, physician-sponsored inclusion within these influential conferences further validates our MicroPulse Laser Therapy, which we believe is well positioned for the current global trend toward value-based healthcare," said Will Moore, IRIDEX President and CEO. "The durable clinical effect combined with the substantial economic benefits for healthcare systems, support the global market opportunity available for our MicroPulse laser technology."In addition, to address the comprehensive ophthalmologist opportunity in the emerging global markets for IRIDEX, there will be a company-sponsored satellite training meeting at the upcoming European Society of Cataract and Refractive Surgeons (ESCRS) conference. ESCRS is Europe's leading organization for cataract and refractive surgeons. The physician-led training will focus on clinical application of IRIDEX' MicroPulse technology as a single-versatile solution to address the needs of comprehensive ophthalmologists in both glaucoma and retina. "With more than 1,400 global views of IRIDEX' most recent webinar, we are seeing strong interest from physicians in MicroPulse Laser Therapy as a durable and economically appealing medical solution for both the glaucoma and retina markets," added Moore. "Recent data regarding MicroPulse laser's effectiveness for patients suffering with glaucoma should prove to be a catalyst for ophthalmologists looking for a versatile solution for their retina, glaucoma, and comprehensive practices."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts